I mentioned in previous articles that genotypes of Chinese hepatitis C patients are mainly 1b and 2a/c, with the number of hepatitis C patients of about 26 million in total but treatment rate of less than 0.5%! The market space is huge.
Since the marketing of DAAs in 2017, many DAAs have entered China, which will change the traditional hepatitis C therapeutic regimen of peginterferon (Peg-IFN-α) in combination with ribavirin. China has begun to enter the era of hepatitis C cure!!
So far, there have been many enterprises marketing DAA hepatitis C drugs in China, and Kawin Technology, Gilead, and AbbVie separately have one relevant drug filed the marketing application to NMPA.
|
Trade name
|
Generic name
|
Therapeutic regimen
|
SVR12
|
China
|
Company
|
|
Daklinza
|
Daclatasvir
|
DCV+ASV, 24 weeks
|
GT1b-24W:91%
|
April 24, 2017
|
BMS
|
|
Sunvepra
|
Asunaprevir
|
|
Olysio
|
Simeprevir
|
SMV, 24/48 weeks
|
GT1-24W/48w:91%
|
August 24, 2017
|
J & J
|
|
Viekirax
|
Ombitasvir / paritaprevir / ritonavir
|
OBV/PTV+DSV, 12 weeks
|
GT1b-12W:99.5%
|
September 21, 2017
|
AbbVie
|
|
Exviera
|
Dasabuvir
|
September 21, 2017
|
|
Sovaldi
|
Sofosbuvir
|
SOF+PR, 12 weeks
|
GT1-12W:94%
|
September 21, 2017
|
Gilead Sciences
|
|
SOF+RBV, 12/24 weeks
|
GT1-24W: 95% GT2-12W: 92% GT3-24W: 95%
|
|
Zepatier
|
Elbasvir
Grazoprevir
|
EBR/GRZ, 12 weeks
|
GT1-12W: 95%
|
April 28, 2018
|
Merck
|
|
Epclusa
|
Sofosbuvir
Velpatasvir
|
SOF+VEL, 12 weeks
|
GT1-12W: 98.4% GT2-12W: 100% GT3-12W: 95%
GT4-12W: 100% GT6-12W: 100%
|
May 30, 2018
|
Gilead Sciences
|
|
Ganovo
|
Danoprevir
|
Danoprevir + PR, 12 weeks
|
GT1-12W: 97% GT4-12W: 100%
|
June 13, 2018
|
Ascletis
|
|
Maviret
|
Glecaprevir
Pibrentasvir
|
GLE+PIB, 8 weeks
|
95%-99.7%#
|
Applied for marketing
|
AbbVie
|
|
Harvoni
|
Ledipasvir
Sofosbuvir
|
LDV+SOF, 12 weeks
|
96%-100%#
|
Applied for marketing
|
Gilead Sciences
|
|
|
KW-136
|
KW-136+SOF
|
N/A
|
Applied for marketing
|
Kawin Technology
|
|
PR: Peginterferon (Peg-IFN-α) in combination with ribavirin
Some data are from the prospectus of Ascletis
#U.S. clinical trial data
|
Gilead, MSD, BMS, and AbbVie have successively published the drug prices as shown in the following table:
|
Enterprise
|
Drug
|
Price
|
|
Gilead
|
Sovaldi
|
RMB 58,980/12 weeks
|
|
BMS
|
Daklinza/Sunvepra
|
RMB 57,810/12 weeks
|
|
AbbVie
|
Viekirax/Exviera
|
RMB 58,968/12 weeks
|
|
MSD
|
Zepatier
|
RMB 59,880/12 weeks
|
|
Ascletis
|
Ganovo
|
RMB 39,996/12 weeks
|
1. Prices of imported drugs are RMB 58,000-60,000/12 weeks
2. Price of the Chinese-produced drug is about RMB 40,000/12 weeks
In terms of the therapeutic regimen:
1. Imported drugs are based on DAA all-oral therapeutic regimen
2. The Chinese-produced drug has the therapeutic regimen of DAA in combination with PR
As the only all-oral, pan-genotypic, single tablet new hepatitis C drug in China, Epclusa has been included in the 2018 Edition National Essential Drugs List of China. Its selling price in China cannot be found at the moment. We look forward to that Epclusa will offer help to the era of hepatitis C cure in China, although inclusion in the said list is no longer the solid backing of sales and its inclusion in the medical insurance payment is not certain. For now, relevant knowledge and consultation rate of Chinese hepatitis C patients must be improved. DAAs are still a big burden to most hepatitis C patients, however, hepatitis C cure is of profound significance.
Read More:
Included in China’s National Essential Drugs List, Can Epclusa Get a Second Wind in China? (1)
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight June 2024: Globalization on the Go
